- 期刊
Mutated KRAS is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
延伸閱讀
- Kang, C. J., Wang, H. M., Lin, C. Y., Fan, K. H., Lee, L. Y., Hsieh, C. H., Huang, C. C., Liao, C. T., & Yen, T. C. (2019). Next Generation Sequencing (NGS) for Prognostic Stratification in Oral Cancer Harboring Lymph Node Metastasis without Extranodal Extension. International Journal of Head and Neck Science, 3(3), 159-172. https://doi.org/10.6696/IJHNS.201909_3(3).0005
- Huang, C. C., Liu, M. T., Pi, C. P., Chang, T. H., Liu, W. S., & Huang, C. Y. (2005). Long-Term Survival with No Evidence of Brain Metastasis in 6 Patients of Limited-Stage Small Cell Lung Cancer Receiving Prophylactic Cranial Irradiation. 放射治療與腫瘤學, 12(3), 207-213. https://doi.org/10.6316/TRO/200512(3)207
- Lin, H. Y., Jen, Y. M., & Hsieh, C. B. (2005). Successful Aggressive Treatment of Isolated Intraabdominal Metastases from a Thymic Carcinoma 16 Years after Surgery and Radiotherapy. Journal of Medical Sciences, 25(2), 87-92. https://www.airitilibrary.com/Article/Detail?DocID=10114564-200504-201304220002-201304220002-87-92
- Chang, T. K., Tsai, H. L., Su, W. C., Huang, C. W., Yeh, Y. S., & Wang, J. Y. (2018). Role of KRAS Mutations in Patients with Metastatic Colorectal Cancer Who Receive Regorafenib Plus FOLFIRI as a Salvage Therapy. 中華民國大腸直腸外科醫學會雜誌, 29(1), 35-44. https://doi.org/10.6312/SCRSTW.2018.29(1).10623
- Chang, T. K. (2018). Role of KRAS mutations in patients with metastatic colorectal cancer who receive regorafenib plus FOLFIRI as a salvage therapy [master's thesis, Kaohsiung Medical University]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0011-2306201817235200